. 2014 Mar;55(3):540–548. doi: 10.1194/jlr.M046342

TABLE 8.

Hepatic lipid content in ASO-treated mice of the indicated genotype

	TG	TC	FC	CE	PL	FFA
WT-C-ASO	86.6 ± 8.3^a	93.3 ± 12.3^a	26.2 ± 3.3^a	67.0 ± 11.7^ac	65.9 ± 6.9^a	49.0 ± 11.1^a
WT-M-ASO	133.1 ± 10.3^b	124.2 ± 14.9^a	30.3 ± 3.2^a	93.9 ± 12.0^ab	64.4 ± 2.9^a	70.7 ± 3.1^a
L-Fabp⁻^/⁻-C-ASO	63.9 ± 9.1^a	92.1 ± 8.3^a	34.3 ± 6.3^a	57.8 ± 5.4^c	87.0 ± 12.1^a	25.3 ± 9.6^b
L-Fabp⁻^/⁻-M-ASO	167.6 ± 31.6^b	135.9 ± 21.6^a	32.6 ± 5.4^a	103.3 ± 16.5^b	82.5 ± 8.9^a	86.3 ± 8.2^a

WT and L-Fabp^−/− mice received either control-ASO or Mttp-ASO for four weeks and were fed a LD for the final 2 weeks, while continuing ASO injection (n = 4–5 per group). Hepatic lipids were extracted and expressed as μg/mg protein except FFA (expressed as nmol/mg protein). The difference between values associated with different superscript letters for the parameters indicated in each vertical column is statistically significant (P < 0.05). TG, triglyceride; TC, cholesterol; FC, free cholesterol; CE, cholesterol ester; PL, phospholipids.